2016
DOI: 10.1039/c5ra22398a
|View full text |Cite
|
Sign up to set email alerts
|

Cyclodextrin polymers as carriers for the platinum-based anticancer agent LA-12

Abstract: Polymeric nanoparticles containing cyclodextrins are currently undergoing clinical trials as nanotherapeutics. In this context, we have synthesized high and low molecular weight β-cyclodextrin polymers and functionalized them with folate to improve their selectivity for cells overexpressing the folic acid receptor. Inclusion complexes of the unfunctionalized and FA-functionalized polymers with the antitumour complex cis-trans-cis-[PtCl2(CH3CO2)2(adamantyl-NH2)(NH3)] (LA-12) have been tested on tumour cells. In… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
27
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
5

Relationship

3
2

Authors

Journals

citations
Cited by 19 publications
(27 citation statements)
references
References 51 publications
0
27
0
Order By: Relevance
“…The poly-merization reaction was performed under basicc onditions using epichlorohydrin (ECH) as the crosslinking reagent. [38,39] The low ECH/monomer ratio (ECH/CyD = 5) ensured the reaction productsw ere oligomers. After Boc deprotection, the product was isolated.…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…The poly-merization reaction was performed under basicc onditions using epichlorohydrin (ECH) as the crosslinking reagent. [38,39] The low ECH/monomer ratio (ECH/CyD = 5) ensured the reaction productsw ere oligomers. After Boc deprotection, the product was isolated.…”
Section: Resultsmentioning
confidence: 99%
“…[37] Recently, we have synthesized functionalized oligomers of b-CyD as drug carriers of the anionic drug diclofenac [38] ando ft he hydrophobic drug LA-12. [39] Inspired by the properties of multicavity systemsand the importanceo fa mino groups in am olecule to exhibit an antiaggregant action, [40] in this work we studied,f or the first time, oligomers of b-CyD as anti-Ab-aggregationa gents. In particular,w esynthesized and assayed the new co-oligomero f6 -(6aminohexyl)amino-6-deoxy-b-cyclodextrin and b-CyD (oCyDH-DA), and the oligomers of b-CyD (oCyD) [39] and 3-amino-3deoxy-b-CyD (oCyDNH 2 ) [38] as antiaggreganta gentst os tudy the effects of multicavity systemsa nd their amino functionalization ( Figure 1).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…[29] Upon adding bCyD to the peptide, the CD spectrum suggested random coil structure, which was maintained even if the sample was kept at room temperature for 1week. This fact indicatedt hat bCyD inhibited conformational changes in Ab (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28) from random coil to b sheet in solution.T he role of bCyD was correlated to its ability to include the Phe19 and Phe20 side chains, which thusi nhibited aggregation.P he19 interactions have ak ey role in the formation of Ab oligomers and fibrils. [30] Twoy ears later,n ew studies on the interactions between Ab-peptide, full length as well as fragments of various sizes, and a-, b-, or gCyD were performed through NMR diffusion studies and 1 HNMR chemical shiftanalysis.…”
Section: Native Cydsmentioning
confidence: 94%
“…[6][7][8][9] In particular,C yDs have mainlyb een used in pharma as drug-deliverys ystems to improvet he solubility and bioavailability of drugs. [10][11][12][13] The properties of CyD can be modulated through their chemical modifications. In fact, covalent conjuga-tion of molecules with different properties provides an attractive approach to build multifunctional systemsa nd fascinating compounds, including enzyme mimics, sensors, and drug carriers.…”
Section: Introductionmentioning
confidence: 99%